Does an Alzheimer's disease susceptibility gene influence the cognitive effects of cancer therapy?

Research output: Contribution to journalReview article

2 Scopus citations


The apolipoprotein E (APOE) e4 allele is the most prevalent genetic risk factor for Alzheimer's disease (AD). APOE e4 carriers suffer greater morbidity from head trauma, stroke, and carbon monoxide poisoning, yet possible interactions between APOE genotype and cancer therapy on cognition are unclear. Neuropathological and biomarker studies of young asymptomatic APOE e4 carriers that show elevated neocortical amyloid and medial temporal neurofibrillary tangles and longitudinal neuropsychological studies that show accelerated memory decline beginning around age 55-60 years define preclinical AD and have set the stage for assessing the potential adverse cognitive effects of cancer therapy in APOE e4 carriers.

Original languageEnglish (US)
Pages (from-to)1739-1742
Number of pages4
JournalPediatric Blood and Cancer
Issue number10
StatePublished - Oct 2014



  • Alzheimer's disease
  • Apolipoprotein E e4

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this